Patient P-02505

Synthetic patientMETA-24 · Day 177 · 45–54 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 GI symptom burden −28% vs expected — Dietary Support Protocol NP-02
Day 64 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 64 Tolerance state changed — Unstable → Improving
Day 71 GI-04 recommended — GI Support Protocol GI-04
Day 72 Patient accepted — Started GI-04 in the companion
Day 80 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 64.

Primary contributors, last 14 days

GI instability+14
Inflammatory activity+6
Treatment adherence-5
Nutritional resilience-4
Toxicity-4

What helped?

Dietary Support Protocol NP-02Day 47
Result: symptom burden −28%
GI Support Protocol GI-04Day 71
Result: no meaningful change

LIFE OS recommendation

Monitoring Escalation ME-01

83%

probability of meaningful tolerance improvement

284 similar trajectories
100% showed improvement
median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

36 min

worsening · -4.9 vs previous 14 d

Sleep duration

Wearable

6.2 h

stable · -0.0 vs previous 14 d

Energy level

Daily log

2.6/10

stable · +0.0 vs previous 14 d

Steps

Wearable

3,907

worsening · -574 vs previous 14 d

GI burden

Companion

72.5/100

worsening · +4.9 vs previous 14 d

Adherence

Companion

37 %

worsening · -4.0 vs previous 14 d

Sleep quality

Wearable

17/100

worsening · -1.1 vs previous 14 d

Glucose, CGM daily mean

CGM

150 mg/dL

stable · +3.1 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 24 from the failing basin, 75 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 42 similar · onset 3 d · confidence 71%
SC-12 Supportive Compound
67% improved among 27 similar · onset 6 d · confidence 71%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 71%
More protein
GI -4.6 next day on high-intake days · n 18

Would not help

GI-04 GI Support Protocol
already tried, no meaningful change
Keep fat low
GI +4.7 next day on high-intake days · n 24
Keep simple carbs low
GI +3.8 next day on high-intake days · n 16
Keep ultra-processed low
GI +3.5 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+4.7detractor · 95%
Protein
-4.6supporter · 95%
Simple carbohydrates
+3.8detractor · 95%
Ultra-processed food
+3.5detractor · 75%
Alcohol
+2.5detractor · 60%
Caffeine
-1no signal · 26%
Histamine load
+0.5no signal · 15%
Insoluble fibre
+0.3no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 25/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 76 bpm
- Wearable3,907 steps/day
- WearableShort sleep window
Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 62
- WearableHRV 19 ms, trending down
Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 73 and rising
Drug metabolism and exposure ↑20
- BloodToxicity index 49

DNA

Fictional pharmacogenomic panel

CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.9 · butyrate capacity 25/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 19 ms
Sleep: 5.9 h
Steps: 3,848
Resting HR: 77 bpm

Daily log: GI score 73, nutritional resilience 35, adherence 37.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02048	17%	S02	—	—	77
P-02115	19%	S14	GI-04	improved	75
P-02575	20%	S14	ME-01	improved	73
P-02550	18%	S01	—	—	70
P-02192	17%	S05	—	—	69
P-02659	21%	S09	—	—	69
P-02214	17%	S08	SC-12	no change	69
P-02083	17%	S13	—	—	69
P-02591	30%	S13	—	—	68
P-02090	17%	S04	—	—	68
P-02265	28%	S07	GI-04	no change	67
P-02530	29%	S07	—	—	67